AZN Shares Dip Amid $400B Merger Rumors – Analysts Still Bullish on AstraZeneca
Discover why AstraZeneca shares dipped after merger rumors, yet analysts stay bullish—key insights into the drugmaker’s pipeline, valuation, and long‑term growth potential.
3 minutes to read